

Hagop Kantarjian, M.D. is professor and chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center, where he is also the Samsung Distinguished Leukemia Chair in Cancer Medicine. He is also a non-resident fellow in health policy at the Rice University Baker Institute. Doctor Kantarjian has received several prestigious honours and awards including the 37th Jeffrey A Gottlieb Memorial Award (2012), the John Mendelsohn Lifetime Scientific Achievement Award (2008), the Joseph H. Burchenal Memorial Award (2013), the Charles A. LeMaistre, M.D. Outstanding Achievement Award in Cancer (2014), and America's Top Doctors, Castle Connolly Medical (2003-present). He was also selected the top Castle Connolly National Physician of the Year Award for Lifetime Achievement (2014). Doctor Kantarjian's research focuses on translational-clinical developmental therapeutics in leukemia. In the past three decades, he has made several contributions that improved prognosis and survival in patients with chronic myeloid leukemia (tyrosine kinase inhibitors, e.g. imatinib, dasatinib, nilotinib, bosutinib which improved the 10-year survival from 20% to 90%), in acute lymphocytic leukemia (HPER-CVAD regimen and its derivatives which improved cure rates from 20% to 60+%), the discovery of decitabine for the treatment of myelodysplastic syndrome, and of clofarabine for the treatment of leukemias, among others. His research and collaborations were the basis for the FDA approvals of over 20 drugs in leukemia. He is an author on over 1,800 peer-reviewed publications.

Present Title & Affiliation

Primary Appointment

Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Department Chair, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Associate Vice President for Global Academic Programs, The University of Texas MD Anderson Cancer Center, Houston, TX

Samsung Distinguished University Chair in Cancer Medicine, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1983 The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Medical Oncology Subspecialty, Hematology/Oncology

1981 American University of Beirut, Beirut, LBN, Internal Medicine, Internal Medicine

1979 American University of Beirut, Beirut, LBN, MD, Medicine

1975 American University of Beirut, Beirut, LBN, BS, Science

1972 American University of Beirut, Beirut, LBN, Baccalaureate

Board Certifications

1990 American Board of Hematology Certification

1985 American Board of Medical Oncology Certification

1983 American Board of Internal Medicine Certification

Honors & Awards

2020 DoCM Excellence in Entrepreneurship Award, MD Anderson Cancer Center

2019 Doctor of Humane Letters honoris causa, American University of Beirut

2015 2015 Lifetime Achievement Award, American Lebanese Medical Association

2014 Giants of Cancer Care Award, OncLive

2014 Charles A. LeMaistre, M.D. Outstanding Achievement Award in Cancer, The University of Texas MD Anderson Cancer Center

2013 2013 Joseph H. Burchenal Memorial Award, American Association for Cancer Research

2012 37th Jeffrey A Gottlieb Memorial Award

2010 Ben Qurrah Award

2009 Best Doctors in America 2009-2010, Best Doctors

2008 The Division of Cancer Medicine, MD Anderson Cancer Center "John Mendelsohn Lifetime Scientific Achievement Award", MD Anderson Cancer Center

2008 The Division of Cancer Medicine, MD Anderson Cancer Center "Waun Ki Hong Award for Excellence in Team Science", MD Anderson Cancer Center

- 2005 America's Top Doctors, Southwestern Region Top Hematologist, Castle Connolly Medical
- 2004 America's Top Doctors, Southwestern Region Top Hematologist, Castle Connolly Medical
- 2003 America's Top Doctors, Southwestern Region Top Hematologist, Castle Connolly Medical
- 1999 Faculty Achievement Award for Clinical Research, UT M.D. Anderson Cancer Center
- 1998 Kelcie Margaret Kana Research Chair, UT M.D. Anderson Cancer Center
- 1997 Outstanding Service to Mankind Award, Leukemia Society of America
- 1997 First Emil J Freireich Award for Outstanding Clinical Research, UT M.D. Anderson Cancer Center
- 1989 Scholar, Leukemia Society of America
- 1985 Special Fellow, Leukemia Society of America
- 1984 Fellow, Leukemia Society of America
- 1983 Fellow Research Award, UT M.D. Anderson Cancer Center
- 1982 Fellow Research Award, UT M.D. Anderson Cancer Center
- 1979 Penrose Award
- 1979 Alpha Omega Alpha Honor Medical Society, American University of Beirut Chapter, Beirut, Lebanon
- 1976 Lange Award

Professional Memberships

National Comprehensive Cancer Network (NCCN)

CML and ALL Panel Representing The University of Texas MD Anderson Cancer Center, 2015 - Present

International Association for Comparative Research on Leukemia and Related Diseases, Mannheim

Member of the Nominating Committee, 2010 - Present

Association of American Physicians

Member, 2004 - Present

American Society for Clinical Oncology

member, 1995 - Present

American Society for Hematology

member, 1992 - Present

American Association for the Advancement of Sciences

Member, 1991 - Present

American Association for Cancer Research

Member, 1990 - Present

American Medical Association

Member, 1985 - Present

Selected Publications

Peer-Reviewed Articles

Kantarjian HM, Hughes TP, Larson RA, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Boquimpani C, Pasquini R, Clark RE, Dubruille V, Flinn IW, Kyrzcz-Krzemien S, Medras E, Zanichelli M, Bendit I, Cacciatore S, Titorenko K, Aimone P, Saglio G, Hochhaus A. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. *Leukemia* 35(2):440-453, 2021. e-Pub 2021. PMID: 33414482.

Kantarjian H, Jabbour E, Topp MS. Blinatumomab for Acute Lymphoblastic Leukemia. *N Engl J Med* 376(23):e49, 2017. PMID: 28591537.

Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, Baccarani M, Deininger MW, Cervantes F, Fujihara S, Ortmann CE, Menssen HD, Kantarjian H, O'Brien SG, Druker BJ, IRIS Investigators. Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. *N Engl J Med* 376(10):917-928, 2017. PMID: 28273028.

Sasaki K, Jabbour EJ, Ravandi F, Short NJ, Thomas DA, Garcia-Manero G, Daver NG, Kadia TM, Konopleva MY, Jain N, Issa GC, Jeanis V, Moore HG, Garris RS, Pemmaraju N, Cortes JE, O'Brien SM, Kantarjian HM. Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis. *Cancer* 122(23):3650-3656, 2016. e-Pub 2016. PMID: 27479888.

Kantarjian HM, Vandendries E, Advani AS. Inotuzumab Ozogamicin for Acute Lymphoblastic Leukemia. *N Engl J Med* 375(21):2100-2101, 2016. PMID: 27959720.

Jabbour E, Kantarjian H, Ravandi F, Thomas D, Huang X, Faderl S, Pemmaraju N, Daver N, Garcia-Manero G, Sasaki K, Cortes J, Garris R, Yin CC, Khoury JD, Jorgensen J, Estrov Z, Bohannan Z, Konopleva M, Kadia T, Jain N, DiNardo C, Wierda W, Jeanis V, O'Brien S. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. *Lancet Oncol* 16(15):1547-55, 2015. e-Pub 2015. PMID: 26432046.

Kantarjian HM, Thomas XG, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J, Gau JP, Chou WC, Buckstein R, Cermak J, Kuo CY, Oriol A, Ravandi F, Faderl S, Delaunay J, Lysák D, Minden M, Arthur C. Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia. *J Clin Oncol* 30(21):2670-2677, 2012. e-Pub 2012. PMID: 22689805.

Tong WG, Estrov Z, Wang Y, O'Brien S, Faderl S, Harris DM, Van Pham Q, Hazan-Halevy I, Liu Z, Koch P, Kantarjian H, Keating MJ, Ferrajoli A. The synthetic heat shock protein 90 (Hsp90)

inhibitor EC141 induces degradation of Bcr-Abl p190 protein and apoptosis of Ph-positive acute lymphoblastic leukemia cells. *Invest New Drugs* 29(6):1206-1212, 2011. e-Pub 2010. PMID: 20533075.

Kantarjian H, O'Brien S. Questions Regarding Frontline Therapy of Acute Myeloid Leukemia. *Cancer* 116(21):4896-4901, 2010. PMID: 20623787.

Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, Pasquini R, Clark RE, Hochhaus A, Hughes TP, Gallagher N, Hoenekopp A, Dong M, Haque A, Larson RA, Kantarjian HM. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. *N Engl J Med* 362(24):2251-9, 2010. e-Pub 2010. PMID: 20525993.

Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. *N Engl J Med* 344(14):1038-42, 2001. PMID: 11287973.

Kantarjian HM, O'Brien S, Smith TL, Cortes J, Giles FJ, Beran M, Pierce S, Huh Y, Andreeff M, Koller C, Ha CS, Keating MJ, Murphy S, Freireich EJ. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. *J Clin Oncol* 18(3):547-61, 2000. PMID: 10653870.

Book Chapters

Kantarjian H, Cortes J. Chronic Myeloid Leukemia. In: *Abeloff's Clinical Oncology*. Sixth. Elsevier: Philadelphia, 1836-1849, 2019.

Kantarjian H, Cortes J. Chronic Myeloid Leukemia. In: *Harrison's Principles of Internal Medicine*. 20th. McGraw-Hill: New York, New York, 748-757, 2018.

Jabbour E, Kantarjian H, Cortes J.. Chronoic Myeloid Leukemia. In: *Management of Hematologic Malignancies*. 1st. Cambridge University Press: New York, 68-80, 2011.

Faderl S, Garcia-Manero G, Kantarjian H.. Myelodysplastic Syndromes (MDS). In: *Management of Hematologic Malignancies*. 1st. Cambridge University Press: New York, 103-115, 2011.

Books (edited and written)

Jabbour E, Kantarjian H, Cortes J, O'Brien S, Faderl S.. *Management of Hematologic Malignancies*. Ed(s) Susan O'Brien, Julie M. Vose and Hagop Kantarjian. 1st. Cambridge University Press: New York, 2011.

Grant & Contract Support

Title: Therapy of AML: Project 4: Clinical Trials in AML

Funding Source:NIH/NCI

Role: Co-Project Leader

Title: The University of Texas MD Anderson Cancer Center SPORE in Leukemia

Funding Source:NIH/NCI

Role: Principal Investigator

Title: Phase I Studies of Targeted Anti-Cancer Therapies; Clinical Core

Funding Source:NIH/NCI

Role: Consultant

Title: Cancer Center Support Grant: Hematologic Malignancies Program

Funding Source:NIH/NCI

Role: Co-Program Leader

Title: Research Training in Academic Medical Oncology

Funding Source:NIH/NCI

Role: Mentor

Title: Full Member Application Affiliated with SWOG

Funding Source:NIH/NCI

Role: Co-Investigator

Title: Randomized study of combined epigenetic therapy

Funding Source:NIH/NCI

Role: Co-Investigator

Title: The Therapy of CML: Project 1: Improving Cytogenetic and Molecular Complete Responses Using High Dose Imatinib Meyslate (Gleevec; ST1571) with or without PEG-Interferon Alpha 2B and GM-CSF

Funding Source:NIH/NCI

Role: Co-Investigator

Title: The Therapy of CML Core A: Administrative Core

Funding Source:NIH/NCI

Role: Co-Program Leader

Title: SPORE in Leukemia Project 1: Epigenetics and Epigenetic Therapy in AML

Funding Source:NIH/NCI

Role: Project Leader

Title: SPORE in Leukemia Career Enhancement Program

Funding Source:NIH/NCI

Role: Program Leader

Title: SPORE in Leukemia Developmental Research Program

Funding Source:NIH/NCI

Role: Program Leader